RESUMO
Preclinical Research & Development The purpose of this study was to assess the interaction and mechanisms of action of the paracetamol-tapentadol combination in the formalin-induced pain model in mice. Paracetamol (56.23-562.3 mg/kg, i.p.) or tapentadol (1-10 mg/kg, i.p.) were administered 15 min prior the intraplantar injection of formalin. The ED50 value of each drug was determined through the dose-response curves. The ED50 values were used to calculate the combinations in three fixed proportions (1:1, 1:3, and 3:1). Naloxone (1 and 5 mg/kg, i.p.), L-NAME (3 mg/kg, i.p.), or glibenclamide (10 mg/kg, i.p.) were administered before the combination of drugs to evaluate the antinociceptive mechanisms of action. The results showed that the combination 1:1 and paracetamol3-tapenadol1 ratios produced additive effects, whereas the paracetamol1-tapentadol3 proportion showed an antinociceptive synergistic interaction. Moreover, naloxone and glibenclamide reversed the antinociceptive activity of the paracetamol-tapentadol mixture. Our results indicate that the paracetamol-tapentadol combination produces an antinociceptive synergistic interaction with the possible participation of ATP-sensitive K+ channels and µ-opioid receptors in the second phase of the formalin-induced pain model in mice.
Assuntos
Canais KATP/agonistas , Medição da Dor/métodos , Dor/tratamento farmacológico , Receptores Opioides mu/agonistas , Tapentadol/administração & dosagem , Acetaminofen/administração & dosagem , Analgésicos não Narcóticos/administração & dosagem , Analgésicos Opioides/administração & dosagem , Animais , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Quimioterapia Combinada , Canais KATP/metabolismo , Masculino , Camundongos , Dor/induzido quimicamente , Dor/metabolismo , Receptores Opioides mu/metabolismoRESUMO
Due to the great global concern regarding bacterial resistance to antibiotics, an ongoing search for new molecules having antibacterial activity is necessary. This study evaluated the antibacterial and anticandidal effects of a hexane extract from the root of Salvia apiana. Salvia extracts at concentrations of 27, 13.5, 6.8 and 3.4mg/ml caused growth inhibition of Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis and Candida albicans. However, no significant effect was observed on Escherichia coli and Candida tropicalis in comparison to vehicle. It was here demonstrated for the first time that Salvia apiana has an important antimicrobial effect on human pathogens of great clinical value, thus opening the field to continue the evaluation of this lamiaceous plant for its future use as a therapeutic agent.
Assuntos
Antibacterianos/farmacologia , Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Salvia/química , Antibacterianos/isolamento & purificação , Antifúngicos/isolamento & purificação , Testes de Sensibilidade a Antimicrobianos por Disco-Difusão , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Hexanos , Extratos Vegetais/isolamento & purificação , Extratos Vegetais/farmacologia , Raízes de Plantas/química , Solventes , Especificidade da EspécieRESUMO
Debido a la gran problemática mundial de la resistencia bacteriana a los antibióticos, es necesaria la búsqueda continua de nuevas moléculas con características antimicrobianas. Este estudio evaluó el efecto antibacteriano y antifúngico de un extracto hexánico proveniente de la raíz de Salvia apiana. Los extractos de salvia a las concentraciones de 27; 13,5; 6,8 y 3,4mg/ml causaron inhibición del crecimiento de Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis y Candida albicans. Sin embargo, no presentaron efecto significativo sobre Escherichia coli y Candida tropicalis al compararse con los valores del vehículo en las valoraciones de difusión en pozo. Se demostró que S. apiana tiene un efecto antimicrobiano significativo sobre patógenos de gran importancia clínica, lo que abre el campo para continuar evaluando a esta lamiácea en vistas a su posible empleo en el futuro como un agente terapéutico
Due to the great global concern regarding bacterial resistance to antibiotics, an ongoing search for new molecules having antibacterial activity is necessary. This study evaluated the antibacterial and anticandidal effects of a hexane extract from the root of Salvia apiana. Salvia extracts at concentrations of 27, 13.5, 6.8 and 3.4mg/ml caused growth inhibition of Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis and Candida albicans. However, no significant effect was observed on Escherichia coli and Candida tropicalis in comparison to vehicle. It was here demonstrated for the first time that Salvia apiana has an important antimicrobial effect on human pathogens of great clinical value, thus opening the field to continue the evaluation of this lamiaceous plant for its future use as a therapeutic agent